Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)
Progression‐free survival · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).
1 finding from 1 review
- Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes onlyHR 0.34 [0.28, 0.42]4 studies · 1677 participantsHigh